Cochrane Abstracts
Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Short Versus Long Duration Infusions of Paclitaxel for Any Advanced Adenocarcinoma: Cochrane Systematic Review." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436580/all/Short_versus_long_duration_infusions_of_paclitaxel_for_any_advanced_adenocarcinoma:_Cochrane_systematic_review.
Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma: Cochrane systematic review. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436580/all/Short_versus_long_duration_infusions_of_paclitaxel_for_any_advanced_adenocarcinoma:_Cochrane_systematic_review. Accessed March 22, 2025.
Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma: Cochrane systematic review. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436580/all/Short_versus_long_duration_infusions_of_paclitaxel_for_any_advanced_adenocarcinoma:_Cochrane_systematic_review
Short Versus Long Duration Infusions of Paclitaxel for Any Advanced Adenocarcinoma: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436580/all/Short_versus_long_duration_infusions_of_paclitaxel_for_any_advanced_adenocarcinoma:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma: Cochrane systematic review
ID - 436580
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436580/all/Short_versus_long_duration_infusions_of_paclitaxel_for_any_advanced_adenocarcinoma:_Cochrane_systematic_review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
